Search

Lacustrine eutrophication is generally considered as an important contributor of carbon emissions to the atmosphere; however, there is still a huge challenge in accuracy estimating carbon emissions from lakes. To test the effect of widely used space-for-time substitution on lake carbon emissions, this study monitored different processes of carbon emissions, including the carbon production potential, dissolved carbon concentrations, and carbon release fluxes in eight lakes along the trophic gradients on a spatial scale and the typical eutrophic Lake Taihu for one year on a temporal scale. Eutrophication promoted carbon production potential, dissolved carbon concentrations, and carbon release fluxes, especially for CH

Heart failure with preserved ejection fraction (HFpEF) is present in nearly half of patients with heart failure. The prevalence of heart failure with normal or near-normal ejection fractions increases more rapidly than in patients with reduced ejection fractions. Angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), aldosterone antagonist, β-blocker, and calcium channel blocker have not shown significant efficacy in HFpEF clinical trials. Sacubitril/Valsartan, combined angiotensin receptor blocker (Valsartan) with neprilysin inhibitor (Sacubitril), was the first-of-its-kind angiotensin receptor-neprilysin inhibitor (ARNI) to be developed. It has shown significant efficacy on HFpEF in recent studies. It is considered that most of the current Sacubitril/Valsartan studies are still concentrated in the field of heart failure, especially heart failure with reduced ejection fraction (HFrEF). This review discusses the latest advances in cardiovascular, renal, and metabolic aspects of Sacubitril/Valsartan, mainly in HFpEF, providing more evidence for further future research on Sacubitril/Valsartan and raising issues that should be paid attention. At the same time, this review will introduce the academic consensus on Sacubitril/Valsartan in treating HFpEF in China.

Patients with chronic kidney disease (CKD) are often complicated with heart failure with preserved ejection fraction (HFpEF). However, several drugs, including angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB), have not shown apparent benefits in terms of morbidity and mortality of HFpEF. PARAMOUNT and other studies have shown the potential benefits of Sacubitril/Valsartan on patients with HFpEF, but its effects on renal function and the effect of low-dose Sacubitril/Valsartan in actual clinical conditions have not been thoroughly evaluated. In our longitudinal and observational research, 353 patients were followed up for 12 weeks. We evaluated renal function [urinary protein, serum creatinine and estimated glomerular filtration rate (eGFR)] and cardiac function [NT-proBNP (brain natriuretic peptide), New York Heart Association (NYHA) classification, left ventricular ejection fraction (LVEF), left atrial width and left ventricular end-diastolic width] at baseline and during follow-up. Worsening renal function (WRF) was defined as an increased serum creatinine≥26.5umol/L or decreased eGFR≥20%. The decline of eGFR in the Sacubitril/Valsartan group was slower than that in the control group (p = 0.021). The outcome of proteinuria in the ACEI/ARB group was significantly better than that in the Sacubitril/Valsartan group (p = 0.001). In terms of echocardiogram, the average left atrial width in Sacubitril/Valsartan group decreased by 1.38 ± 3.02 mm, which was significantly lower than that in the ACEI/ARB group (p = 0.02). The increase of urine protein class in the ACEI/ARB group increased the risk of WRF with statistical significance (OR = 2.36, 95%CI 1.01-5.49, p = 0.047), but no statistical significance was found in all the patients or Sacubitril/Valsartan group. In conclusion, Sacubitril/Valsartan could more effectively slow down renal function decline and reverse myocardial remodeling in patients with CKD and HFpEF than ACEI/ARB, even at low doses, though its protective effect on urinary protein is not as good as that of ACEI/ARB.

In-vehicle human–machine interface (HMI) mainly refers to the T-shaped panel system with instruments, centre console, gear lever and other components installed. For intelligent vehicles, the high level of intelligent interconnection may to some extent make drivers lack situational safety awareness and reduce the usability of the system. Thus, this study attempted to establish a relationship between design features and system usability of the in-vehicle panels. From the perspective of visual ergonomics, the panels were deconstructed into design features to determine 36 samples to be studied. After dividing each sample into four areas of interest (AOI), eye movement and subjective preference data were collected to quantify the user experience. Artificial neural network (ANN) and support vector machine (SVM) were used in the study. Nevertheless, conventional learning algorithms often underwent deficiencies in accuracy and robustness in the detection of multifarious kinds of panels. Therefore, the parameters of the two models were tuned to deal with the noise common in user experience data. The determinant coefficients, mean-square errors and mean relative errors of the two models showed that the SVM model had a higher accuracy, smaller error and was more stable in the learning of user experience of HMI design features, which could provide a method for the layout design and evaluation of T-shaped instrument panel.

Due to the shielding effect of the outermost electronic layer 5s and 5p of rare earth, the near-infrared photoluminescence (PL) of Er3+ can not be easily affected by the external environment. However, we have regulated the near-infrared PL of Er3+ by changing temperature, which is ascribed to the phase transition of BaTiO3 from tetragonal to cubic phase and the presence of impurity. It also found that the redshift of wavelength in samples containing tetragonal phase BaTiO3 can reach 13 nm, which is never observed in other materials. The center wavelength shifts from 1530 nm to 1543 nm as the temperature rises from 20 to 200 °C. Moreover, the full width at half maximum (FWHM) of samples containing cubic phase has a growth of 6 nm (up to 85 nm) with increasing temperature. It indicated that temperature-induced phase transition can be an important method to modulate the PL of Er3+ in BaTiO3 with impurity.